TD Cowen initiated coverage on Prime Medicine
$PRME
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TD Cowen initiated coverage of Prime Medicine with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2024 | $10.00 | Buy | H.C. Wainwright |
| 5/16/2024 | $10.00 | Neutral → Buy | Citigroup |
| 4/22/2024 | $17.00 | Buy | Chardan Capital Markets |
| 4/8/2024 | Buy | TD Cowen | |
| 4/3/2024 | $12.00 | Outperform | Wedbush |
| 1/16/2024 | $18.00 → $9.00 | Buy → Hold | Stifel |
| 12/8/2023 | $10.00 | Neutral | Citigroup |
| 10/9/2023 | $19.00 | Outperform | BMO Capital Markets |
H.C. Wainwright initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $10.00
Citigroup upgraded Prime Medicine from Neutral to Buy and set a new price target of $10.00
Chardan Capital Markets initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $17.00
Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND and/or CTA filing expected in 1H 2026 CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today presented data from multiple studies showcasing the potential of its proprietary, universal lipid nanoparticle (LNP) platform to precisely deliver Prime Editor
-- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, being held October 22-25, 2024 in Rome, and the American Association for the Study of Liver Diseases (AASLD), being held November 15-19, 2024 in San Diego. "
-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's Disease Program Toward Expected IND Application and/or CTA in 1H 2026 -- -- Today Announced Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-cell Therapies -- -- Together with $110 Million Upfront Consideration Received Under Agreement with Bristol Myers Squibb, Anticipated Cost Savings are Expected to Extend
SC 13G - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13D - Prime Medicine, Inc. (0001894562) (Subject)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
10-Q - Prime Medicine, Inc. (0001894562) (Filer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. "I am delighted to welcome Allan to Prime Medicine. He brings tremendou
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of Directors with appointment of Jeff Marrazzo, former CEO of Spark Therapeutics -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's second patent, No. 11,643,652, and allowed third patent application, No. 17/751,599 -- -- Cash, cash equivalents, investments and restricted cash balance of $263.0 million as of March 31, 2023 -- CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME)
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's third patent, No. 11,795,452 --
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $10.
Citigroup analyst Samantha Semenkow upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $10 price target.